Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (441-450 of 458) with videos related to

Pageof 46
Sort By:
The New England Journal of Medicine|January 12, 2017
Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Ghassan El-Haddad, Edward Wolin, et al.
JAMA Oncology|April 7, 2017
An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal CancerJessica A Zerillo, Maartje G Schouwenburg, Annelotte C M van Bommel, et al.
Lancet (London, England)|June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Cancers|August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD DatabaseFang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
The New England Journal of Medicine|October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal CancerScott Kopetz, Axel Grothey, Rona Yaeger, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysisRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Journal of the National Cancer Institute|December 22, 2017
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram ProjectKatrin M Sjoquist, Lindsay A Renfro, R John Simes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic AdenocarcinomaPascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
Pageof 46

Showing results (441-450 of 458) with videos related to

Sort By:
Pageof 46
The New England Journal of Medicine|January 12, 2017
Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Ghassan El-Haddad, Edward Wolin, et al.
JAMA Oncology|April 7, 2017
An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal CancerJessica A Zerillo, Maartje G Schouwenburg, Annelotte C M van Bommel, et al.
Lancet (London, England)|June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Cancers|August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD DatabaseFang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
The New England Journal of Medicine|October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal CancerScott Kopetz, Axel Grothey, Rona Yaeger, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysisRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Journal of the National Cancer Institute|December 22, 2017
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram ProjectKatrin M Sjoquist, Lindsay A Renfro, R John Simes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic AdenocarcinomaPascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD GroupKaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
Pageof 46